Panacea Biotec ends COVID Vaccine MoU entered with Refana

Panacea Biotec informed that the termination is due to delays in project timelines and difficulty in moving ahead with the joint venture.

Published On 2020-08-25 09:09 GMT   |   Update On 2020-08-25 10:07 GMT
Advertisement

New Delhi: Panacea Biotec has terminated the MOU for the development, manufacture, and supply of a vaccine for COVID-19 in collaboration with Refana. The MOU, executed on June 9, 2020, was terminated with effect from August 21, 2020.

The company informed that the termination is due to delays in project timelines and difficulty in moving ahead with the joint venture.

It will not pursue the development of the COVID-19 vaccine project in collaboration with Refana and will not make any investment in the joint venture company proposed under the MOU, which was approved by the shareholders of the Company on July 17, 2020, informed the company through a statement.

Advertisement
"This is in continuation to our earlier intimation letters dated June 10, 2020, and June 16, 2020, regarding Memorandum of Understanding ("MOU") dated June 09, 2020, entered into between the Company and REFANA Inc. The USA, a Delaware corporation incorporated under the laws of the state of Delaware, the United States for global development, manufacturing, and distribution of the Covid-19 vaccine, through a 50:50 Joint Venture Company," the company said in a filing.
Medical dialogues had earlier reported that Panacea Biotec advanced its response to address the unprecedented challenges of COVID-19 by collaborating with Refana Inc. USA to make COVID-19 vaccine widely accessible around the world in an equitable manner through a Joint Venture company to be based in Ireland.

The collaboration aimed to bring to patients a whole inactivated virus-based vaccine for COVID-19. Under the collaboration, Panacea Biotec was responsible for product development and commercial manufacturing, with the Joint Venture undertaking clinical development and regulatory submissions across the World. Both Panacea and Refana would undertake sales and distribution of the vaccine in their respective territories.

Also Read: Panacea Biotec, Refana Enter Landmark Collaboration For COVID-19 Vaccine

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News